Clinical trialPhase 1Unknown
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
A Multicenter, Open-label Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of GH21 Capsules in Subjects With Advanced Solid Tumors
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 20 February 2022
- Listed end
- 20 February 2025
- Enrollment
- 68 participants
- Sites
- 9
- Primary outcomes
- Determination of Maximum Tolerated Dose (MTD) of GH21.; Characterize the Safety of GH21
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 16 July 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.